|
목적 : To compare treatment outcomes of photodynamic therapy (PDT), anti-vascular endothelial growth factor (VEGF) therapy, and combination therapy (PDT with the anti-VEGF therapy ranibizumab) for polypoidal choroidal vasculopathy (PCV).
방법 : Retrospective study was conducted. Among 62 eyes (62 patients), 19 eyes received PDT only (PDT group), 23 received intravitreal ranibizumab injections only (anti-VEGF group), and 20 received combined PDT with anti-VEGF therapy (combination group). Best-corrected visual acuity [BCVA, logarithm of minimum angle resolution (logMAR)] and recurrence after treatment were compared at baseline and 1, 3, 6, 12, and 24 months.
결과 : Mean baseline BCVA was 0.68±0.36 logMAR in PDT group, 0.67±0.43 logMAR in anti-VEGF group, and 0.64±0.35 logMAR (P=0.723) in combination group. Both PDT group and combination group maintained visual improvement by 0.08 logMAR (P=0.183) and 0.25 logMAR (P=0.013) at 24 months, respectively. Anti-VEGF group failed to maintain visual improvement, worsening by 0.07 logMAR (P=0.673) at 24 months. During follow-up, nine PDT group eyes (47.4%), 15 anti-VEGF group eyes (64.9%), and 10 combination group eyes (50.0%) showed at least one recurrence.
결론 : Visual outcomes but not recurrence rates were better with combination therapy compared to PDT and anti-VEGF monotherapy for 24-month follow-up.
|